These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 7741777)

  • 1. Steady-state plasma kinetics of slow-release propafenone, its two isomers and its main metabolites.
    Volz M; Mitrovic V; Thiemer J; Schlepper M
    Arzneimittelforschung; 1995 Mar; 45(3):246-9. PubMed ID: 7741777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma concentrations of propafenone--chirality and metabolism.
    Volz M; Mitrovic V; Schlepper M
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):370-5. PubMed ID: 7952800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E; Müller-Peltzer H; Hollmann M
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms].
    Mastropasqua F; Totaro P; Massari F; Pitzalis MV; Rizzon P
    Cardiologia; 1998 Jun; 43(6):617-23. PubMed ID: 9675961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
    Lardoux H; Maison Blanche P; Marchand X; Canler A; Rouesnel P; Bleinc D; Péraudeau P; Scheck F
    Ann Cardiol Angeiol (Paris); 1996 Oct; 45(8):469-79. PubMed ID: 8952741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G; Capucci A; Strocchi E; Marchesini B; Baroni M; Frabetti L; Ambrosioni E; Magnani B
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.
    Nielsen H; Sørum C; Rasmussen V; Madsen JK; Hansen JF
    Acta Cardiol; 1990; 45(5):359-63. PubMed ID: 1704168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
    Cerqueira PM; Cesarino EJ; Mateus FH; Mere Y; Santos SR; Lanchote VL
    Chirality; 1999; 11(7):591-7. PubMed ID: 10423287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2D6*10 genotype on propafenone pharmacodynamics in Chinese patients with ventricular arrhythmia.
    Cai WM; Xu J; Chen B; Zhang FM; Huang YZ; Zhang YD
    Acta Pharmacol Sin; 2002 Nov; 23(11):1040-4. PubMed ID: 12421483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantioselective plasma protein binding of propafenone: mechanism, drug interaction, and species difference.
    Hong Y; Tang Y; Zeng S
    Chirality; 2009 Jul; 21(7):692-8. PubMed ID: 18937289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group.
    Zoble RG; Kirsten EB; Brewington J
    Clin Pharmacol Ther; 1989 May; 45(5):535-41. PubMed ID: 2721109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady state kinetics of a fatty alcohol-based slow-release nifedipine for once a day application.
    Woodcock BG; Merz PG; Rietbrock S; Rudolph B; Pfleiderer S
    Arzneimittelforschung; 1993 Jul; 43(7):734-6. PubMed ID: 8369004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects.
    Cai WM; Chen B; Cai MH; Chen Y; Zhang YD
    Br J Clin Pharmacol; 1999 May; 47(5):553-6. PubMed ID: 10336580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
    Mörike K; Kivistö KT; Schaeffeler E; Jägle C; Igel S; Drescher S; Fux R; Marx C; Hofmann U; Engel C; Wagner F; Delabar U; Meisner C; Bail D; Böhm JO; Gleiter CH; Ziemer G; Rein JG; Hellberg KD; Eichelbaum M; Schwab M
    Clin Pharmacol Ther; 2008 Jul; 84(1):104-10. PubMed ID: 18167502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.